Aerocrine’s FeNO technology is standard practice in NHANES data by the CDC to define airway inflammation in US population

Aerocrine’s FeNO technology is standard practice in NHANES data by the CDC to
define airway inflammation in US population

SOLNA, Sweden – 5 December 2011 – Aerocrine announced that the Center for
Disease Control for Health Statistics measured FeNO as a standard practice in
examining the components on respiratory health, using the NIOX MINO device.

Aerocrine is very pleased the Centers for Disease Control and Prevention (CDC),
through its National Center for Health Statistics, has recognized the importance
of utilizing fractional exhaled nitric oxide (FeNO) measurements in a national
survey to help understand the prevalence of airway inflammation in the U.S.
population. The National Health and Nutrition Examination Survey (NHANES;
http://www.cdc.gov/nchs/nhanes.htm), a continuous program with an evolving,
need-based focus on a variety of health and nutrition measurements, is used to
determine the prevalence of major diseases and risk factors for diseases.
Uniquely combining interviews and physical examinations with laboratory tests,
the survey examines a national representation of people located across the
country, and measuring FeNO is currently a standard procedure when administering
the survey.

The measurement of FeNO is one of two examination components on respiratory
health in the NHANES 2007-2008 and 2009-2010 surveys sponsored by the National
Heart, Lung, and Blood Institute of the National Institutes of Health and FeNO
will continue to be collected for at least two more years. In these surveys,
FeNO is measured using the Aerocrine NIOX MINO®, a portable, hand-held nitric
oxide (NO) analyzer (Aerocrine AB, Solna, Sweden) cleared by the U.S. Food and
Drug Administration (FDA) in 2008. The objective of the FeNO data collection is
to examine baseline FeNO values and reference ranges for the U.S. healthy
population, as well as those with asthma and chronic obstructive pulmonary
disease (COPD) and those who are smokers. The data collection is also intended
to help define the prevalence of undiagnosed airway inflammation in the U.S. and
to examine the association between airway inflammation, other measurements of
lung function and capacity, and physical and laboratory measures. Survey
participant’s ages six to 79 years are eligible for FeNO testing, and valid
measurements obtained in 13,275 study participants using the NIOX MINO were
recently released for analysis.

We are confident that through this assessment FeNO will continue to demonstrate
its utility in the diagnosis and monitoring of patients with inflammatory airway
diseases such as asthma, and it will enable physicians to provide a more
personalized approach to the treatment of these conditions.

For more information, contact:

Kathy Rickard, Chief Medical Officer, Aerocrine, Inc., telephone (919) 749-6708

Chip Neff, President, Aerocrine, Inc., telephone (919) 696-4267